~~CLAIMS~~

~~1. A method for inhibiting the progression of structural damage in a subject suffering from Rheumatoid Arthritis, comprising administering to the subject an effective amount of sarilumab.~~

~~2. The method according to claim 1, wherein the subject achieves after at least 24 weeks of treatment a change from baseline (BL) in the modified Van der Heijde total Sharp score (mTSS) of at most 0.6.~~

~~3. The method according to claim 1 or 2, wherein the subject achieves after at least 52 weeks of treatment a change from baseline (BL) in the modified Van der Heijde total Sharp score (mTSS) of at most 1.~~

~~4. The method of any one of claims 1 to 3, wherein the subject was previously ineffectively treated for rheumatoid arthritis by administering at least one disease-modifying anti-rheumatic drug (DMARD) selected from the group consisting of methotrexate, leflunomide, sulfasalazine and hydroxychloroquine.~~

~~5. The method of any of claims 1 to 4, wherein the method comprises administering to the subject an effective amount of sarilumab and an effective amount of methotrexate, leflunomide, sulfasalazine and/or hydroxychloroquine.~~

~~6. The method of any of claims 1 to 5, wherein the method comprises administering to the subject an effective amount of sarilumab and an effective amount of methotrexate.~~

~~7. The method of any of claims 4-6, wherein methotrexate is administered between 6 to 25 mg per week.~~

~~8. The method of any of claim 1 to 7, wherein sarilumab is administered subcutaneously.~~

~~9. The method of any of claim 1 to 8, wherein sarilumab is administered at about 150 mg per two weeks.~~

~~10. The method of any of claim 1 to 8, wherein sarilumab is administered at about 200 mg per two weeks.~~

~~11. The method of any of claims 1-10, wherein sarilumab is administered to the subject for at least 52 weeks.~~

~~12. The method of claim 9, wherein the subject achieves after at least 24 weeks of treatment a change from baseline (BL) in the modified Van der Heijde total Sharp score (mTSS) of at most 0.6.~~

~~13. The method of claim 9, wherein the subject achieves after at least 24 weeks of treatment a change from baseline (BL) in the modified Van der Heijde total Sharp score (mTSS) of about 0.54.~~

~~14. The method of claim 9, wherein the subject achieves after at least 52 weeks of treatment a change from baseline (BL) in the modified Van der Heijde total Sharp score (mTSS) of at most 1.~~

~~15. The method of claim 9, wherein the subject achieves after at least 52 weeks of treatment a change from baseline (BL) in the modified Van der Heijde total Sharp score (mTSS) of about 0.90.~~

~~16. The method of claim 10, wherein the subject achieves after at least 24 weeks of treatment a change from baseline (BL) in the modified Van der Heijde total Sharp score (mTSS) of at most 0.2.~~

~~17. The method of claim 10, wherein the subject achieves after at least 24 weeks of treatment a change from baseline (BL) in the modified Van der Heijde total Sharp score (mTSS) of about 0.13.~~

~~18. The method of claim 10, wherein the subject achieves after at least 52 weeks of treatment a change from baseline (BL) in the modified Van der Heijde total Sharp score (mTSS) of at most 0.3.~~

~~19. The method of claim 10, wherein the subject achieves after at least 52 weeks of treatment a change from baseline (BL) in the modified Van der Heijde total Sharp score (mTSS) of about 0.25.~~

~~20. A method for improving physical function in a subject suffering from Rheumatoid Arthritis, comprising administering to the subject an effective amount of sarilumab.~~

~~21. The method of claim 20, wherein the subject achieves after at least 16 weeks of treatment a change from baseline (BL) in the Health Assessment Questionnaire Disability Index (HAQ-DI) of at least -0.5.~~

~~22. The method of claim 20, wherein the subject achieves after at least 24 weeks of treatment a change from baseline (BL) in the Health Assessment Questionnaire Disability Index (HAQ-DI) of at least -0.6.~~

~~23. The method of claim 20, wherein the subject achieves after at least 52 weeks of treatment a change from baseline (BL) in the Health Assessment Questionnaire Disability Index (HAQ-DI) of at least -0.7.~~

CLAIMS

1. Use of an antibody comprising a heavy chain variable region comprising SEQ ID NO:2 and a light chain variable region comprising SEQ ID NO:3, for the manufacture of a pharmaceutical composition for obtaining inhibition of the progression of structural damage in a subject suffering from Rheumatoid Arthritis, wherein said medicament is to be administered with an effective amount of methotrexate, and wherein the antibody is to be administered subcutaneously to the subject between 150 and 200 mg per two weeks.

2. Use of an antibody comprising a heavy chain variable region comprising SEQ ID NO:2 and a light chain variable region comprising SEQ ID NO:3 in a combination with methotrexate for the preparation of a medicament for obtaining inhibition of the progression of structural damage in a subject suffering from Rheumatoid Arthritis wherein the medicament is formulated to be subcutaneously administer said antibody to a subject at between 150 and 200 mg per two weeks.

3 The use according to claim 1 or 2, wherein inhibition of the progression of structural damage is characterised in that the subject achieves after at least 24 weeks of treatment a change from baseline (BL) in the modified Van der Heijde total Sharp score (mTSS) of at most 0.6.

4. The use of any one of claims 1 to 3, wherein inhibition of the progression of structural damage is characterised in that the subject achieves after at least 52 weeks of treatment a change from baseline (BL) in the modified Van der Heijde total Sharp score (mTSS) of at most 1.

5. The use of any one of claims 1 to 4, wherein the subject was previously ineffectively treated for rheumatoid arthritis by administering methotrexate.

6. The use of any one of claims 1 to 5, wherein methotrexate is to be administered between 6 to 25 mg per week.

7. The use of any one of claims 1 to 6, wherein the antibody is sarilumab.

8. The use of any of claim 1 to 7, wherein the antibody is to be administered at 150 mg per two weeks.

9. The use of any of claim 1 to 7, wherein the antibody is to be administered at 200 mg per two weeks.

10. The use of any of claims 1 to 9, wherein the antibody is to be administered to the subject for at least 52 weeks.

11. The use of any one of claims 1 to 10, wherein inhibition of the progression of structural damage is characterised in that the subject achieves after at least 24 weeks of treatment a change from baseline (BL) in the modified Van der Heijde total Sharp score (mTSS) of at most 0.2.

12. The use of any one of claims 1 to 11, wherein inhibition of the progression of structural damage is characterised in that the subject achieves after at least 24 weeks of treatment a change from baseline (BL) in the modified Van der Heijde total Sharp score (mTSS) of about 0.13.

13. The use of any one of claims 1 to 12, wherein inhibition of the progression of structural damage is characterised in that the subject achieves after at least 52 weeks of treatment a change from baseline (BL) in the modified Van der Heijde total Sharp score (mTSS) of at most 0.3.

14. The use of any one of claims 1 to 13, wherein inhibition of the progression of structural damage is characterised in that the subject achieves after at least 52 weeks of treatment a change from baseline (BL) in the modified Van der Heijde total Sharp score (mTSS) of about 0.25.